


Product Name : TAPI-2
Cat. No. : PC-42086
CAS No. : 187034-31-7
Molecular Formula : C₁₉H₃₇N₅O₅
Molecular Weight : 415.5276
Target : Matrix Metalloproteinase (MMP)
Solubility : DMSO: ≥ 22 mg/mL



Biological Activity

TAPI-2 is a broad-spectrum inhibitor of **TNF- α converting enzyme** (TACE, ADAM17), ADAMs, and other MMPs, inhibits ADAM8, 10, 12, and TACE with K_i values of 10, 3, 100, and 0.12 μ M, respectively.

TAPI-2 inhibits PMA-induced shedding of cell surface proteins, such as TGF- α , β amyloid precursor protein, L-selectin, and IL-6 receptor α subunit in CHO cells with IC_{50} of 10 μ M.

TAPI-2 reverses the malignant phenotype in a breast cancer cell line by preventing mobilization of the growth factors TGF- α and amphiregulin.

TAPI-2 binds to hmeprin with inhibition constants IC_{50} 20 \pm 10 μ M for hmeprin β subunit and 1.5 \pm 0.27 nM for hmeprin α subunit.

TAPI-2 dramatically decreases the protein levels of NICD and its downstream target HES-1 in both HCP-1 and HT29 cells.

TAPI-2 significantly decreases the CSC phenotype by -50% in treated CRC cell lines.

TAPI-2 is an ADAM17 inhibitor but not ADAM10 inhibitor.

References

Moss ML, et al. *Anal Biochem*. 2007 Jul 15;366(2):144-8.

Parvathy S, et al. *Biochem J*. 1997 Oct 1;327 (Pt 1):37-43.

Kenny PA, et al. *J Clin Invest*. 2007 Feb;117(2):337-45.

Fiorucci S, et al. *Aliment Pharmacol Ther*. 1998 Nov;12(11):1139-53.

Caution: Product has not been fully validated for medical applications. Lab Use Only!